Clinical Trials List
2024-09-01 - 2032-12-31
Phase III
Recruiting5
ICD-10C19
Malignant neoplasm of rectosigmoid junction
ICD-10Z51.12
Encounter for antineoplastic immunotherapy
ICD-9154.0
Malignant neoplasm of rectosigmoid junction
-
Trial Applicant
Johnson & Johnson
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/02/01
Investigators and Locations
Co-Principal Investigator
- Po-Wen Lin 無
- 黃盈慈 無
- 黃怡璇 無
- Shang-Hung Chen 無
- Jui-Hung Tsai 無
- Peng-Chan Lin 無
- 黃怡菁 無
- 鍾秉軒 無
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 林宗哲 無
- 梁逸歆 無
- 陳柏邑 無
- TSUNG-HAO LIU 無
- 李佳真 無
- Chih-Hung Hsu 無
- Chiun Hsu 無
- TA-CHEN HUANG 無
- 呂理駿 無
- YU-YUN SHAO 無
- 莊建淮 無
- 陳國興 無
- Ann-Lii Cheng 無
- Ying-Chun Shen 無
- 張端瑩 無
- 郭弘揚 無
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 余紹銘 無
- 張境夫 無
- 黃振洋 無
- Ming-Mo Hou 無
- Wen-Chi Chou 無
- Jen-Shi Chen 無
- 賴盈傑 無
- 呂嘉偉 無
- Yung-Chia Kao 無
- Tsai-Sheng Yang 無
- Mengting Peng 無
- 黃文冠 無
- Chia-Hsun Hsieh 無
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
50 participants
-
Global
1000 participants
